UB
CPRX

UMB Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

UMB Bank’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.9K Buy
681
+91
+15% +$2.17K ﹤0.01% 1665
2025
Q4 		$13.8K Buy
590
+160
+37% +$3.56K ﹤0.01% 1692
2025
Q3 		$8.47K Buy
430
+3
+0.7% +$62 ﹤0.01% 1742
2025
Q2 		$9.27K Buy
427
+10
+2% +$236 ﹤0.01% 1629
2025
Q1 		$10.1K Buy
417
+135
+48% +$3.04K ﹤0.01% 1545
2024
Q4 		$5.88K Hold
282
– – ﹤0.01% 1652
2024
Q3 		$5.61K Buy
282
+140
+99% +$2.6K ﹤0.01% 1690
2024
Q2 		$2.2K Buy
142
+92
+184% +$1.43K ﹤0.01% 1740
2024
Q1 		$797 Buy
+50
New +$753 ﹤0.01% 1850

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UMB Bank's CPRX Position: Q1 2026 in Review

UMB Bank increased its Catalyst Pharmaceutical (CPRX) stake by 15% in Q1 2026, buying an estimated $2.17K and bringing the position to 681 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

UMB Bank first reported a position in CPRX in Q1 2024 and has held it in 9 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • UMB Bank held 681 shares of Catalyst Pharmaceutical worth $16.9K as of Q1 2026.
  • UMB Bank bought 91 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.17K.
  • Catalyst Pharmaceutical made up ﹤0.01% of UMB Bank's portfolio in Q1 2026, its #1665 holding.
  • UMB Bank first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on UMB Bank's 13F filing for Q1 2026, filed 11 May 2026.